Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant hepatitis B vaccine + hepatitis B immune globulin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination therapy consists of a recombinant hepatitis B vaccine (produced in yeast) and Hepatitis B Immune Globulin (HBIG). It is primarily used for the prevention of mother-to-child transmission (MTCT) of the hepatitis B virus (HBV) in neonates born to HBsAg-positive mothers. The recombinant vaccine provides active immunity by stimulating the host's immune system to produce protective antibodies against the hepatitis B surface antigen (HBsAg). Simultaneously, HBIG provides immediate passive immunity by supplying pre-formed antibodies that neutralize circulating HBV particles. This dual approach is the standard of care for post-exposure prophylaxis in infants born to infected mothers. The specific regimen evaluated by the Jiangsu Province Centers for Disease Control and Prevention involves a 10 mcg dose of the recombinant vaccine and a 200 IU dose of HBIG.
- Other names
- recombinant hepatitis B vaccine + HBIGHepB vaccine + HBIG
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on recombinant hepatitis B vaccine + hepatitis B immune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant hepatitis B vaccine + hepatitis B immune globulin.